Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea

Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea

Endocrine therapy is the mainstay treatment for hormone receptor-positive ductal carcinoma in situ. The aim of this study was to examine the long-term secondary malignancy risk of tamoxifen therapy. The data of patients diagnosed with breast cancer between January 2007 and December 2015 were retriev...

Full description

Bibliographic Details
Main Authors: Dooreh Kim, Jooyoung Oh, Jeong-Ho Seok, Hye Sun Lee, Soyoung Jeon, Chang Ik Yoon
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Diagnostics
Subjects:
secondary cancer
tamoxifen
endocrine therapy
ductal carcinoma in situ
DCIS
Online Access:https://www.mdpi.com/2075-4418/13/4/792

Internet

https://www.mdpi.com/2075-4418/13/4/792

Similar Items